Disitamab Vedotin (RC48) Clinical Trials
3 recruitingDrug
Phase 23
Showing 1–3 of 3 trials
Recruiting
Phase 2
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
HER2-low Breast Cancer
The First Affiliated Hospital with Nanjing Medical University37 enrolled1 locationNCT07446452
Recruiting
Phase 2
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study
mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20 enrolled1 locationNCT07093866
Recruiting
Phase 2
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University74 enrolled1 locationNCT07065435